A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

H. Polman, Chris; O’Connor, Paul; Havrdová, Eva; Hutchinson, Michael; Kappos, Ludwig; H. Miller, David; Theodore Phillips, J.; Lublin, Fred; Giovannoni, Gavin; Wajgt, A; Toal, Martin; Lynn, Frances; Panzara, Michael; Sandrock, Alfred

doi:10.1056/nejmoa044397

Public

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Published in New England Journal of Medicine • Mar 1, 2006

Authors:

Chris H. Polman

Paul O’Connor

Eva Havrdová

Abstract

BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. METHODS: Of a total of 942 patients, 627 were randomly assigned to...

Subject

Natalizumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!